Therapeutic efficacy of 166 Holmium siloxane in microbrachytherapy of induced glioblastoma in minipig tumor model.

Autor:	Khoshnevis M; Université de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France., Brown R; Inserm, UMR1037 CRCT, Toulouse, France., Belluco S; Université de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France., Zahi I; Advanced Accelerator Applications, a Novartis Company, Saint-Genis-Pouilly, France., Maciocco L; Advanced Accelerator Applications, a Novartis Company, Saint-Genis-Pouilly, France., Bonnefont-Rebeix C; Université de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France., Pillet-Michelland E; Université de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France., Tranel J; Inserm, UMR1037 CRCT, Toulouse, France., Roger T; Université de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France., Nennig C; EVEON, 305 rue Aristide Berges, Montbonnot Saint Martin, France., Oudoire P; EVEON, 305 rue Aristide Berges, Montbonnot Saint Martin, France., Marcon L; Institut Lumière Matière, UMR CNRS 5306, UCBL, Campus LyonTech - La Doua, Villeurbanne, France., Tillement O; Institut Lumière Matière, UMR CNRS 5306, UCBL, Campus LyonTech - La Doua, Villeurbanne, France., Louis C; Nano-H SAS, 305 rue des Fours, Fontaines Saint Martin, France., Gehan H; Nano-H SAS, 305 rue des Fours, Fontaines Saint Martin, France., Bardiès M; Inserm, UMR1037 CRCT, Toulouse, France., Mariani M; Advanced Accelerator Applications, a Novartis Company, Colleretto Giacosa, France., Muzio V; Advanced Accelerator Applications, a Novartis Company, Colleretto Giacosa, France., Meunier JP; Advanced Accelerator Applications, a Novartis Company, Saint-Genis-Pouilly, France., Duchemin C; Subatech, CNRS/IN2P3, IMT Atlantique, Université de Nantes, Nantes Cedex, France., Michel N; Subatech, CNRS/IN2P3, IMT Atlantique, Université de Nantes, Nantes Cedex, France.; IP Arronax, Saint Herblain, France., N'Tsiba E; Subatech, CNRS/IN2P3, IMT Atlantique, Université de Nantes, Nantes Cedex, France.; IP Arronax, Saint Herblain, France., Haddad F; Subatech, CNRS/IN2P3, IMT Atlantique, Université de Nantes, Nantes Cedex, France.; IP Arronax, Saint Herblain, France., Buronfosse T; Université de Lyon, VetAgro Sup, Laboratoire de Biologie Médicale, Marcy L'Etoile, France., Carozzo C; Université de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France., Ponce F; Université de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France.; Université de Lyon, VetAgro Sup, Service de Cancérologie, Marcy L'Etoile, France.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 Nov 07; Vol. 12, pp. 923679. Date of Electronic Publication: 2022 Nov 07 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.923679
Abstrakt:	Glioblastoma is considered the most common malignant primary tumor of central nervous system. In spite of the current standard and multimodal treatment, the prognosis of glioblastoma is poor. For this reason, new therapeutic approaches need to be developed to improve the survival time of the glioblastoma patient. In this study, we performed a preclinical experiment to evaluate therapeutic efficacy of 166 Ho microparticle suspension administered by microbrachytherapy on a minipig glioblastoma model. Twelve minipigs were divided in 3 groups. Minipigs had injections into the tumor, containing microparticle suspensions of either 166 Ho (group 1; n = 6) or 165 Ho (group 2; n = 3) and control group (group 3; n = 3). The survival time from treatment to euthanasia was 66 days with a good state of health of all minipigs in group 1. The median survival time from treatment to tumor related death were 8.6 and 7.3 days in groups 2 and control, respectively. Statistically, the prolonged life of group 1 was significantly different from the two other groups (p < 0.01), and no significant difference was observed between group 2 and control (p=0.09). Our trial on the therapeutic effect of the 166 Ho microparticle demonstrated an excellent efficacy in tumor control. The histological and immunohistochemical analysis showed that the efficacy was related to a severe 166 Ho induced necrosis combined with an immune response due to the presence of the radioactive microparticles inside the tumors. The absence of reflux following the injections confirms the safety of the injection device. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Khoshnevis, Brown, Belluco, Zahi, Maciocco, Bonnefont-Rebeix, Pillet-Michelland, Tranel, Roger, Nennig, Oudoire, Marcon, Tillement, Louis, Gehan, Bardiès, Mariani, Muzio, Meunier, Duchemin, Michel, N’Tsiba, Haddad, Buronfosse, Carozzo and Ponce.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu